Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201108005065/en/
Vifor Pharma and Angion Biomedica Corp. (Angion) announced the signing of a licensing agreement for the commercialization of ANG-3777, currently developed for treatment of delayed graft function (DGF) and cardiac surgery-associated acute kidney injury (CSA-AKI). ANG-3777 was engineered to mimic the biological activity of HGF, activating critical pathways in the body’s natural organ repair process following an acute organ injury.
Under the terms of the agreement, Vifor Pharma will receive an exclusive global license, excluding China, Taiwan, Hong Kong and Macau, for all ANG-3777 nephrology indications.Angion will receive up to USD 80 million which includes a 30 million upfront payment, a 30 million equity investment and 20 million in clinical study milestone payments. Additionally Angion is eligible to receive up to USD 260 million in market access related milestones upon approval in US and EU, further payments in the form of sales milestones, and tiered royalties on global net sales up to 40% at the high end of the royalty range.
“This agreement highlights the leadership position that Vifor Pharma has developed in the nephrology space and the fact that it has become the company of choice for organizations committed to partnering innovative nephrology focused assets“ said Stefan Schulze, Chief Executive Officer of Vifor Pharma. “Angion is an excellent partner with an outstanding expertise leading to the development of this exciting asset and other pipeline products. We look forward to working closely with Angion who will be responsible for the ongoing development program of ANG-3777 and to leveraging our commercial expertise to bring this highly promising, innovative treatment with a unique mode of action to patients suffering from DGF and CSA-AKI. These are both critical conditions, currently without any effective or approved therapies.”
“Vifor Pharma is one of the world leaders in the nephrology space and we are very excited to partner with them on the commercialization of ANG‑3777 for nephrology indications,” stated Dr. Jay Venkatesan, President and CEO of Angion. “This is a major milestone for the team at Angion who has worked for many years to develop ANG-3777 as a therapy for patients with acute kidney injuries. We look forward to phase-III data in DGF towards the end of 2021 and working with Vifor Pharma to potentially bring ANG-3777 to nephrology patients worldwide.”
Addressable patients with DGF is estimated to be about 15,000 and approximately 110,000 with CSA-AKI in the US/EU5 each year.
Angion will be responsible for conducting the ongoing nephrology-focused clinical development programs. Angion and Vifor Pharma will share responsibilities for regulatory filings in the licensed territories and Vifor Pharma will be responsible for all commercialization activities related to nephrology indications in all licensed territories.
Vifor Pharma will host a conference call and webcast today, 9 November 2020 at 2:00 pm (CET), to discuss the license agreement.
Conference call link to get the dial-in number (open 30 minutes prior to start of the webcast): https://conferencing.swisscom.ch/conference/x/cU-8I7D0aXQc.
Webcast link: https://stream.swisscom.ch/vifor/20201109/
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit www.viforpharma.com
Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion’s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), which activates the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. ANG-3777 is currently in clinical trials investigating its impact on acute organ injury, including two forms of acute kidney injury and in acute lung injury. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for fibrotic diseases using a precision-medicine approach. For further information, please visit www.angion.com
ANG-3777 is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), which activates the c-Met cascade of pathways involved in tissue repair and organ repair. ANG-3777 has a substantially longer half-life than HGF and Angion believes ANG-3777 has the potential to be a first-in-class therapeutic addressing acute organ injury. The ongoing clinical trials of ANG-3777 include a placebo-controlled Phase 3 registration trial in transplant-associated acute kidney injury, also known as delayed graft function, a Phase 2 proof-of-concept trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass surgery, and a Phase 2 proof-of-concept trial in patients with acute lung injury associated with COVID-19 pneumonia. In 2018, Sinovant Sciences and Angion signed a development and licensing agreement for ANG-3777 in Greater China.
During cardiac surgery, the use of cardiopulmonary bypass during the procedure may cause or exacerbate kidney injury as a result of reduced blood flow, non-pulsatile circulation, rupture of red blood cells creating oxidant damage and other causes. CSA-AKI is caused by many factors, including shear stress during cardiopulmonary bypass and injuries from nephrotoxic drugs and contrast agents. In addition, an important driver of CSA-AKI is ischemia-reperfusion injury, which is similar to the injury seen in DGF. There are no approved pharmacological treatments.1
Delayed graft function is a severe form of acute kidney injury resulting from ischemia-reperfusion injury following kidney transplantation. It is distinct from transplant rejection and is most commonly seen in recipients of deceased-donor kidneys. In delayed graft function, the kidney fails to adequately filter the blood and patients require dialysis within the first week after transplantation.2 Dialysis does not treat acute kidney injury, but instead is renal replacement therapy for impaired kidneys. Patients with delayed graft function are more likely to experience transplant failure and have a higher mortality rate.3, 4, 5
Bellomo R, et al. “Acute kidney injury.” The Lancet (2012); 380: 756-766.
Centers for Disease Control and Prevention. “Dialysis Safety.” October 2017.
Shoskes D, et al. “Delayed Graft Function in Renal Transplantation: Etiology, Managment and Long-term Significance.” The Journal of Urology (1996); 155: 1831-1840.
Brown, et al., “Duration of acute kidney injury impacts long-term survival after cardiac surgery. The Annals of thoracic surgery. (2010); 90(4).
Schnuellee, P et al., “Comparison of early renal function parameters for the prediction of 5-year graft survival after kidney transplantation.” Nephrology Dialysis Transplantation (2006); 22: 235–245.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For Vifor Pharma:
Global Head Corporate Communications
+41 79 957 96 73
Head of Investor Relations
+41 58 851 66 90
Cherilyn Cecchini, M.D.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
O-RAN ALLIANCE Announces New Specifications and Demos, First Open Test and Integration Centers and Its June 29 Industry Summit24.6.2021 00:22:00 CEST | Press release
O-RAN ALLIANCE welcomes stc as its new operator member, building up the world-wide community of 29 mobile network operators committed to deployment of open and intelligent Radio Access Networks (RAN). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005961/en/ O-RAN Logical Architecture (Graphic: Business Wire) 33 New or Updated O-RAN Specifications Released since March 2021 On June 17, 2021, the O-RAN ALLIANCE published another 33 specification documents, including 11 new titles. Among others these new specifications include: Management interface, timing and synchronization for Transport The baseline for Non-Real-Time Radio Intelligent Controller (Non-RT RIC) and Near-Real-Time RIC Architecture and interfaces (E2, A1, F1/X2/Xn) Certification and badging guidelines and parts of end-to-end, inter-operability and conformance testing For more details on the new specifications, please check this O-RAN blog post. To download
Grand Prize Winner Announced in $5M IBM Watson AI XPRIZE Competition23.6.2021 19:30:00 CEST | Press release
XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, and IBM Watson, IBM’s AI technology for business, today announced the Grand Prize Winner in the $5M IBM Watson AI XPRIZE Challenge. First launched in 2016, the five-year global competition looked to accelerate adoption of artificial intelligence (AI) technologies and spark creative, innovative and audacious demonstrations of the technology that are truly scalable to solve societal grand challenges. Winning first place honors isZzapp Malaria, in second place is Aifred Health, followed by Marinus Analytics. These finalists were selected out of a pool of 10 semifinalists following presentations of their solutions to a panel of judges during an event held at TED headquarters in New York City last year. A $3 million grand prize, $1 million second place prize, and $500k third place prize will be awarded to the teams. In total, over 150 teams throughout the world joined the compe
New Lattice CertusPro-NX General Purpose FPGAs Deliver Advanced System Bandwidth and Memory Capabilities to Edge Applications23.6.2021 18:00:00 CEST | Press release
Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today launched the Lattice CertusPro™-NX general purpose FPGA family. As the fourth device family based on the Lattice Nexus™ platform to be launched in just 18 months, CertusPro-NX continues Lattice’s commitment to FPGA innovation with leadership power efficiency, the highest bandwidth in the smallest form factor in comparison to similar devices, and as the only FPGAs in their class with support for LPDDR4 external memory. With advanced performance capabilities and the highest logic density currently available on a Nexus-based device, CertusPro-NX FPGAs are designed to accelerate application development for the Communications, Compute, Industrial, Automotive, and Consumer markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005270/en/ The Lattice CertusPro-NX general purpose FPGA (Graphic: Business Wire) “Many Edge devices require
Echodyne Expands Market for Leading CUAS Radar, EchoGuard23.6.2021 18:00:00 CEST | Press release
Echodyne, the radar platform company, announced today substantial enhancements to its industry-leading radars, adding a new radar for international markets, a new product for special operations-type applications, a ruggedized radome, and continuing improvements in software and performance. Together, these product developments represent significant advancements to its breakthrough radar technology, MESA®. With customers in defense, national security, and critical infrastructure protection, Echodyne radars have become a core component for counter-UAS, border security, and base and perimeter 3D surveillance solutions. The products and improvements include: EchoGuard International. The new EchoGuard radar has RoHS3 construction and is compliant with CE Radio Equipment Directive (RED) compliance for EU customers, per Type Examination Certificate per 2014/53/EU Radio Equipment directive. EchoGuard spectrum expansion. Many jurisdictions allow for RadioLocation use at 24.05-24.25 GHz, and Echo
Walton Enters the Single-Family Build-to-Rent Market Using its 81,000 Acre Land Portfolio Throughout the U.S.23.6.2021 15:18:00 CEST | Press release
Walton Global Holdings has launched a build-to-rent (BTR) line of business that will leverage its more than 81,000 acres of land assets throughout the U.S. to create near-term opportunities for single-family home rental developments. Walton is a global real estate investment and land asset management company with US$3.4 billion under management making the company one of the largest pure-play residential landowners in North America. The launch of Walton’s BTR business provides the company with an immediate competitive advantage during a time when established land parcels are hard to come by for many organizations in this market. Walton’s core products have been pre-development land and land development for more than 42 years. Through its core business, Walton specializes in land acquisition to zoning and entitlements partnering with top national homebuilders throughout the U.S. Walton has already identified 17 near-term opportunities and is in advanced negotiations with a select group o
A European Leader in Retail for Automotive Launches Its Data Exchange Platform Powered by Dawex23.6.2021 15:00:00 CEST | Press release
Dawex, the leading data exchange and data marketplace technology company, today announced a European leader in retail for automotive has chosen Dawex technology to deploy its Data Exchange Platform to distribute, exchange and commercialize data products securely, in compliance with regulations. Relying on Dawex technology, the Data Exchange facilitates access to data products, accelerates data circulation and monetization, and orchestrates a data ecosystem. This data hub enables the entire sector to propose new services, improve productivity and efficiency, mitigate risk, and generate new revenue streams. Our customer’s Data Marketplace empowers participating organizations to build strong data partnerships where data providers and data acquirers benefit from the appropriate governance models to ensure participants remain in full control over the data they share, with whom they share it with, and for which usage. Dawex Data Exchange technology brings the technical, contractual, financia
IDEMIA Brings Boarding Security to Los Angeles International Airport (LAX)23.6.2021 15:00:00 CEST | Press release
IDEMIA is facilitating a facial recognition system to help U.S. Customs and Border Protection (CBP) increase air passengers’ security and border control at Los Angeles International Airport (LAX), one of the busiest airports in the world. The technology has been deployed in LAX’s new West Gates at Tom Bradley International Terminal and is a one-stop safety solution for passengers, airlines, and airports alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005420/en/ (Photo: Business Wire) The deployment is part of a contract awarded by Los Angeles World Airports (LAWA) to EASIER, a leader in e-gate technology. In alignment with protection measures defined by the U.S. Congress, passengers will now get to experience a faster, more accurate, and touchless boarding experience. LAX is just one of multiple airports where IDEMIA’s facial recognition technology is deployed in conjunction with CBP and an example of the long-te